Results 1 to 10 of about 28,587 (260)
One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19 [PDF]
Frontiers in Pharmacology, 2023 The ongoing Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has imposed a huge threat to public health across the world.
Yuanyuan Yu +6 more
doaj +2 more sources
Bronchodilators use in patients with COPD
International Journal of COPD, 2015 Yaa-Hui Dong,1,2,* Chia-Lin Hsu,3,4,* Ying-Ying Li,5 Chia-Hsuin Chang,6,7 Mei-Shu Lai2,7 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ...
Dong YH, Hsu CL, Li YY, Chang CH, Lai MS
doaj +3 more sources
Effects of Short-Acting Bronchodilators Added to Maintenance Tiotropium Therapy
Chest, 2007 Background: Combining bronchodilators has been shown to be beneficial in patients with COPD. The additive effects of short-acting bronchodilators added to maintenance tiotropium therapy, however, are unknown.
Huib A M Kerstjens
exaly +2 more sources
European Journal of Heart Failure, 2010 Heart failure (HF) and chronic obstructive pulmonary disease are common partners. Bronchodilators are associated with adverse cardiovascular outcomes in patients with pulmonary disease. The outcome of patients with HF prescribed bronchodilators is poorly
Nathaniel M Hawkins +2 more
exaly +2 more sources
Expert Opinion on Drug Metabolism and Toxicology, 2018 Bronchodilators are central to the symptomatic treatment of chronic obstructive pulmonary disease (COPD). Their pharmacodynamic aspects have been extensively described, but the pharmacokinetic profile of these drugs is much less well known.
Maria Gabriella Matera +2 more
exaly +2 more sources
An update on bronchodilators in Phase I and II clinical trials
Expert Opinion on Investigational Drugs, 2012 Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD at all stages of the disease, and are critical in the symptomatic management of asthma.
Mario Cazzola +2 more
exaly +1 more source
Clinical Case Reports, 2023 Acute severe bronchial asthma is a chronic inflammatory disease characterized by hyperresponsiveness of the airways leading to bronchoconstriction. We present a case of refractory life‐threatening bronchial asthma that was managed with sevoflurane gas ...
Satheesh Munusamy +3 more
doaj +1 more source
Pharmacotherapeutic strategy for COPD patients: focus on dual bronchodilators
Медицинский совет, 2021 For two decades, the GOLD Initiative has consistently identified the use of bronchodilators as a priority in the pharmacotherapeutic strategy for COPD.
A. I. Sinopalnikov
doaj +1 more source
Pharmaceuticals, 2023 This work aims to investigate bronchodilator delivery with the use of different vaping drug delivery systems (VDDS) by determining the dose equivalence delivered in relation to different references: a clinical jet nebulizer, a pMDI (pressurized metered ...
Mariam Chaoui +5 more
doaj +1 more source
The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
Sinusitis, 2022 Chronic obstructive pulmonary disease (COPD) is a global public health burden that stands out as a leading cause of mortality around the world, especially in less developed countries.
Ricardo G. Figueiredo +2 more
doaj +1 more source